Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 85/100

Termination Rate

20.0%

1 terminated out of 5 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

3Total
Not Applicable (1)
P 1 (1)
P 2 (1)

Trial Status

Recruiting2
Unknown1
Withdrawn1
Terminated1

Clinical Trials (5)

Showing 5 of 5 trials
NCT06060613Phase 1RecruitingPrimary

Safety and Efficacy of OBX-115 in Advanced Solid Tumors

NCT03716193Not ApplicableTerminated

Measurement of the Partial Pressure of Oxygen in Cutaneous Tumors Using Electron Paramagnetic Resonance (EPR) Oximetry

NCT05867004Recruiting

Blocking TNF to Potentiate the ICI-dependent Immune Awakening in Melanoma

NCT05689112Unknown

Microscopy Imaging of Whole-mount Stained Human Tissues

NCT03972046Phase 2Withdrawn

Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma

Showing all 5 trials

Research Network

Activity Timeline